Author Archives: Mary Chapman

Race, poverty, healthcare access influence disparities in lupus care

Disparities in lupus care and outcomes in the U.S. are influenced by structural and social determinants such as race, ethnicity, socioeconomics, education, and healthcare access. These are the findings of a study by the Lupus Foundation of America (LFA) through its Addressing health Inequities in Minorities (AIM)…

Horizon: Phase 2 trial of daxdilimab in SLE fails to meet main goal

A Phase 2 clinical trial assessing the safety and effectiveness of daxdilimab for systemic lupus erythematosus (SLE) didn’t show a statistically significant difference between the experimental therapy and a placebo regarding the proportion of patients who showed signs of reduced disease activity while lowering their daily corticosteroid dose. The…

Lupus Landmark Study launched to improve research, personalized care

The Lupus Research Alliance (LRA) and its clinical research affiliate, Lupus Therapeutics, have launched the largest, long-term prospective observational study in lupus with the goal of developing new, personalized treatments for the chronic immune system disorder. The Lupus Landmark Study is a key part of Lupus…

Advocates lobby Congress about improving lupus care access

Hundreds of lupus supporters converged on Capitol Hill recently for the first time since 2019 to show their support for policies that would improve patient access to care, hear from lupus experts, and recognize those who’ve advocated for patients. The National Lupus Advocacy Summit, presented April 23-25 by…

7 lupus research projects win LRA Innovation Award grants

Seven projects led by research teams from the U.S. and Europe have been announced as the recipients of the latest round of Lupus Research Alliance (LRA) Lupus Innovation Award (LIA) grants, which can total up to $300,000. The awards provide support — up to $150,000 annually for two…

New public-private consortium forms to advance lupus treatments

The Lupus Research Alliance (LRA) has convened a public-private consortium to bring together the U.S. Food and Drug Administration (FDA) and key stakeholders to overcome scientific hurdles in lupus and advance new personalized treatments. The patient-focused Lupus Accelerating Breakthroughs Consortium (Lupus ABC) will also be made up…

Program Seeks to Boost Minority Participation in Clinical Trials

To help dermatologists and nephrologists understand the importance of minority participation in lupus clinical trials and why such participation is lacking, the American College of Rheumatology (ACR) is announcing new continuing medical education (CME) offerings. Specifically, the new CME provides the specialists with information about racial disparities in…

Lupus Foundation of America Grants Fellowships for 6 Young Scientists

The six recipients of the 2022 Lupus Foundation of America (LFA) fellowships for young scientists will each pursue research in key areas of lupus investigation, including cardiovascular risks, genetics, biomarkers, and environmental factors. Awarded through the Gina M. Finzi Memorial Student Summer Fellowship Program, the grants are…